Thu-Tam Huynh

Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial.

G. Hortobagyi, L. Pusztai, E. Swisher, 2023, The Lancet. Oncology.

Results of a phase II randomized trial of cisplatin +/- veliparib in metastatic triple-negative breast cancer (TNBC) and/or germline BRCA-associated breast cancer (SWOG S1416).

G. Hortobagyi, L. Pusztai, E. Swisher, 2020 .